chloroquine has been researched along with Mental Disorders in 23 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the frequency of adverse events, particularly neuropsychiatric effects, from mefloquine and from chloroquine plus proguanil as used for malaria chemoprophylaxis." | 7.69 | Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. ( Barrett, PJ; Bradley, DJ; Clarke, PD; Emmins, PD, 1996) |
| "To compare the frequency of adverse events, particularly neuropsychiatric effects, from mefloquine and from chloroquine plus proguanil as used for malaria chemoprophylaxis." | 3.69 | Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. ( Barrett, PJ; Bradley, DJ; Clarke, PD; Emmins, PD, 1996) |
| "To perform a systematic review on the psychiatric adverse effects of chloroquine (CQ) and hydroxychloroquine (HCQ); to summarize what is known about psychiatric adverse effects of these drugs; to compare clinical trials, populational studies, and case report studies; and to increase awareness of the potential psychiatric adverse effects of these drugs." | 3.01 | Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies. ( Cao, B; Chakravarty, S; Greenshaw, AJ; Liu, YS; Passos, IC; Talarico, F, 2023) |
| "However, coronavirus disease 2019 (COVID-19) treatments, themselves, must be considered as potential catalysts for new-onset neuropsychiatric symptoms in COVID-19 patients." | 1.72 | Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect? ( Camejo-Avila, NA; Collado Espinal, IB; Delgado-Noguera, LA; Ferro, C; Flora-Noda, DM; Forero-Peña, DA; Hernandez, MM; Landaeta, ME; Maricuto, AL; Morantes Rodríguez, CG; Mozo Herrera, IP; Páez Paz, J; Paniz-Mondolfi, AE; Perez-Garcia, LA; Sordillo, EM; Velásquez, VL, 2022) |
| " In this study, aiming to investigate these adverse events (AEs) using a large self-reporting database, we conducted a disproportionality analysis for the detection of neuropsychiatric AE signals associated with the use of chloroquine (or hydroxychloroquine), reported to FDA Adverse Event Reporting System (FAERS) database between the fourth quarter of 2012 and the fourth quarter of 2019." | 1.56 | Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. ( Iwata, A; Mano, T; Sato, K; Toda, T, 2020) |
| "Psychosis is caused by interactions with other drugs or by pharmacogenetic vulnerabilities that cause heightened responses to chloroquine or mefloquine alone, mediated through dopamine, acetylcholine, serotonin, P-glycoprotein, inhibited cortical activity, deranged calcium homeostasis, and impaired synaptogenesis." | 1.33 | Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis. ( Alisky, JM; Chertkova, EL; Iczkowski, KA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (26.09) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Forero-Peña, DA | 1 |
| Hernandez, MM | 1 |
| Mozo Herrera, IP | 1 |
| Collado Espinal, IB | 1 |
| Páez Paz, J | 1 |
| Ferro, C | 1 |
| Flora-Noda, DM | 1 |
| Maricuto, AL | 1 |
| Velásquez, VL | 1 |
| Camejo-Avila, NA | 1 |
| Sordillo, EM | 1 |
| Delgado-Noguera, LA | 1 |
| Perez-Garcia, LA | 1 |
| Morantes Rodríguez, CG | 1 |
| Landaeta, ME | 1 |
| Paniz-Mondolfi, AE | 1 |
| Talarico, F | 1 |
| Chakravarty, S | 1 |
| Liu, YS | 1 |
| Greenshaw, AJ | 1 |
| Passos, IC | 1 |
| Cao, B | 1 |
| Sato, K | 1 |
| Mano, T | 1 |
| Iwata, A | 1 |
| Toda, T | 1 |
| Javelot, H | 1 |
| El-Hage, W | 1 |
| Meyer, G | 1 |
| Becker, G | 1 |
| Michel, B | 1 |
| Hingray, C | 1 |
| Yahya, AS | 1 |
| Khawaja, S | 1 |
| Chukwuma, J | 1 |
| Gressier, F | 1 |
| Verstuyft, C | 1 |
| Becquemont, L | 1 |
| Falissard, B | 1 |
| Corruble, E | 1 |
| Nessaibia, I | 1 |
| Siciliano, D | 1 |
| Tahraoui, A | 1 |
| Walters, S | 1 |
| Bhatt, N | 1 |
| Medford, AR | 1 |
| Filler, R | 1 |
| Saha, R | 1 |
| Rietz, G | 1 |
| Petersson, H | 1 |
| Odenholt, I | 1 |
| MUSTAKALLIO, KK | 2 |
| PIHKANEN, TA | 2 |
| PUTKONEN, T | 2 |
| RAB, SM | 1 |
| SPENCE, HY | 1 |
| CASHMAN, JW | 1 |
| GALLAGHER, JA | 1 |
| NEFF, L | 1 |
| Alisky, JM | 1 |
| Chertkova, EL | 1 |
| Iczkowski, KA | 1 |
| Lench, P | 1 |
| Bhatia, MS | 1 |
| Malik, SC | 1 |
| Barrett, PJ | 1 |
| Emmins, PD | 1 |
| Clarke, PD | 1 |
| Bradley, DJ | 1 |
| Corbett, EL | 1 |
| Doherty, JP | 1 |
| Behrens, RH | 1 |
| Dollow, S | 1 |
| Bachmeyer, C | 1 |
| Gérard, P | 1 |
| Bouraya, D | 1 |
| Devergie, B | 1 |
| Laribi, K | 1 |
| Cadranel, JF | 1 |
| Snellman, AM | 1 |
| Søndergaard, HP | 1 |
1 review available for chloroquine and Mental Disorders
| Article | Year |
|---|---|
Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies.
Topics: Anxiety; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; M | 2023 |
22 other studies available for chloroquine and Mental Disorders
| Article | Year |
|---|---|
Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect?
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Mental Disorders; SARS-CoV-2 | 2022 |
Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Betacoronavirus; Chloroquine; Databases, Factual; Fem | 2020 |
COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
Topics: Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Hydr | 2020 |
The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
Topics: Adrenal Cortex Hormones; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hyd | 2020 |
Psychiatric Side Effects of Chloroquine.
Topics: Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Mental Disorders | 2020 |
Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19?
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Forecasting; Humans; Hydroxychloroquine; Men | 2020 |
Reversible cerebellar signs due to sarcoid-related severe hypercalcaemia.
Topics: Chloroquine; Dehydration; Glucocorticoids; Humans; Hypercalcemia; Ketoconazole; Male; Mental Disorde | 2013 |
Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Chloroqui | 2009 |
[Many travellers suffer of side-effects of malaria prophylaxis].
Topics: Antimalarials; Chloroquine; Drug Eruptions; Gastrointestinal Diseases; Humans; Malaria; Mefloquine; | 2002 |
Toxic psychosis during chloroquine treatment.
Topics: Chloroquine; Humans; Mental Disorders; Psychoses, Substance-Induced; Psychotic Disorders | 1962 |
Chloroquine psychosis?
Topics: Chloroquine; Humans; Mental Disorders; Psychoses, Substance-Induced; Psychotic Disorders | 1962 |
Two cases of chloroquine psychosis.
Topics: Chloroquine; Humans; Mental Disorders; Psychoses, Substance-Induced; Psychotic Disorders | 1963 |
PEACE CORPS HEALTH EXPERIENCES ABROAD.
Topics: Amebiasis; Chloroquine; Communicable Diseases; Dermatology; Dysentery; Dysentery, Amebic; Gastroente | 1963 |
DRUG REACTIONS IN ADOLESCENCE.
Topics: Adolescent; Chloroquine; Depersonalization; Depression; Depressive Disorder; Dermatology; Fear; Huma | 1964 |
Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis.
Topics: Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chloroquine; Drug Interactio | 2006 |
Malaria prophylaxis. Psychological problems after mefloquine and chloroquine.
Topics: Chloroquine; Humans; Malaria; Mefloquine; Mental Disorders | 1995 |
Psychiatric complications of chloroquine.
Topics: Antimalarials; Case-Control Studies; Child; Chloroquine; Humans; India; Mental Disorders; Seizures | 1995 |
Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Health Surveys; Hospitalizatio | 1996 |
Adverse events associated with mefloquine. Study in returned travellers confirms authors' findings.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Humans; Mefloquine; Mental Disorders; Proguani | 1996 |
Adverse events associated with mefloquine. Risk-benefit ratio must be taken into account.
Topics: Antimalarials; Chloroquine; Drug Combinations; Humans; Mefloquine; Mental Disorders; Proguanil; Risk | 1996 |
[Neuropsychiatric disorders induced by chloroquine].
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Mental Disorders | 1997 |
[Potentially severe and often insidious adverse psychological effects of chloroquine].
Topics: Adult; Chloroquine; Female; Humans; Mental Disorders; Psychoses, Substance-Induced | 1985 |